These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 17275736

  • 1. Fragments, network biology and designing multiple ligands.
    Morphy R, Rankovic Z.
    Drug Discov Today; 2007 Feb; 12(3-4):156-60. PubMed ID: 17275736
    [Abstract] [Full Text] [Related]

  • 2. [Design of multiple targeted drugs].
    Guo YS, Guo ZR.
    Yao Xue Xue Bao; 2009 Mar; 44(3):276-81. PubMed ID: 19449524
    [Abstract] [Full Text] [Related]

  • 3. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective.
    Zhao H.
    Drug Discov Today; 2007 Feb; 12(3-4):149-55. PubMed ID: 17275735
    [Abstract] [Full Text] [Related]

  • 4. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA.
    Chem Res Toxicol; 2011 Sep 19; 24(9):1420-56. PubMed ID: 21790149
    [Abstract] [Full Text] [Related]

  • 5. Network pharmacology: the next paradigm in drug discovery.
    Hopkins AL.
    Nat Chem Biol; 2008 Nov 19; 4(11):682-90. PubMed ID: 18936753
    [Abstract] [Full Text] [Related]

  • 6. Conciliating binding efficiency and polypharmacology.
    Mestres J, Gregori-Puigjané E.
    Trends Pharmacol Sci; 2009 Sep 19; 30(9):470-4. PubMed ID: 19717193
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Designing multiple ligands - medicinal chemistry strategies and challenges.
    Morphy R, Rankovic Z.
    Curr Pharm Des; 2009 Sep 19; 15(6):587-600. PubMed ID: 19199984
    [Abstract] [Full Text] [Related]

  • 9. From magic bullets to designed multiple ligands.
    Morphy R, Kay C, Rankovic Z.
    Drug Discov Today; 2004 Aug 01; 9(15):641-51. PubMed ID: 15279847
    [Abstract] [Full Text] [Related]

  • 10. Molecular conceptor for training in medicinal chemistry, drug design, and cheminformatics.
    Cohen C, Fischel O, Cohen E.
    Chem Biol Drug Des; 2007 Jan 01; 69(1):75-82. PubMed ID: 17313460
    [Abstract] [Full Text] [Related]

  • 11. In silico fragment screening by replica generation (FSRG) method for fragment-based drug design.
    Fukunishi Y, Mashimo T, Orita M, Ohno K, Nakamura H.
    J Chem Inf Model; 2009 Apr 01; 49(4):925-33. PubMed ID: 19354203
    [Abstract] [Full Text] [Related]

  • 12. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD.
    J BUON; 2007 Sep 01; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [Abstract] [Full Text] [Related]

  • 13. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly.
    Erlanson DA, Hansen SK.
    Curr Opin Chem Biol; 2004 Aug 01; 8(4):399-406. PubMed ID: 15288250
    [Abstract] [Full Text] [Related]

  • 14. Preclinical formulations for discovery and toxicology: physicochemical challenges.
    Neervannan S.
    Expert Opin Drug Metab Toxicol; 2006 Oct 01; 2(5):715-31. PubMed ID: 17014391
    [Abstract] [Full Text] [Related]

  • 15. Fragment-based lead discovery: a chemical update.
    Erlanson DA.
    Curr Opin Biotechnol; 2006 Dec 01; 17(6):643-52. PubMed ID: 17084612
    [Abstract] [Full Text] [Related]

  • 16. An efficient in silico screening method based on the protein-compound affinity matrix and its application to the design of a focused library for cytochrome P450 (CYP) ligands.
    Fukunishi Y, Hojo S, Nakamura H.
    J Chem Inf Model; 2006 Dec 01; 46(6):2610-22. PubMed ID: 17125201
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
    Beaumont K, Smith DA.
    Curr Opin Drug Discov Devel; 2009 Jan 01; 12(1):61-71. PubMed ID: 19152214
    [Abstract] [Full Text] [Related]

  • 19. Ligand-based vascular targeting of disease.
    Rybak JN, Trachsel E, Scheuermann J, Neri D.
    ChemMedChem; 2007 Jan 01; 2(1):22-40. PubMed ID: 17154429
    [Abstract] [Full Text] [Related]

  • 20. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era.
    Frye SV.
    Chem Biol; 1999 Jan 01; 6(1):R3-7. PubMed ID: 9889153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.